What Does Danaher (DHR) Do? — Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters Overview
A roundup of Danaher (DHR) stock price, outlook, earnings, revenue, and related stocks. As a leading global healthcare tools and diagnostics franchise, bioprocessing demand recovery, the diagnostics cycle, and capital return policy are the key variables driving its stock, earnings, and related-stock narrative, while a diversified business segment structure contributes to stability.
Danaher (DHR) is a global healthcare tools and diagnostics group headquartered in Washington, D.C., United States, with roots dating back to 1969. Through an acquisition-and-redeployment operating model, the company has steadily expanded its portfolio across bioprocessing, diagnostics, and life science tools.
Danaher operates a diversified business segment portfolio across healthcare tools and diagnostics, including life sciences (such as Cytiva), diagnostics (Beckman Coulter, Leica, Cepheid), and bioprocessing (Cytiva, Pall). It holds a global leadership position across both the diagnostics and life sciences pillars.
💰 How does Danaher make money?
| Business Segment | Revenue Weight | Description | ||||||
|---|---|---|---|---|---|---|---|---|
| Bioprocessing | Core growth pillar | Purification, filtration, and cell culture for biopharmaceutical manufacturing | ||||||
| Diagnostics | Mainstay | Clinical chemistry, immunoassay, and molecular diagnostics | ||||||
| Life Sciences | Diversification pillar | Mass spectrometry, protein, and genomics tools |
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
| TMO | Thermo Fisher Scientific Inc | $576.77 | +0.1% | $214.3B | 31.0 | 4.1 | 13.53% | 0.32% |
| A | Agilent Technologies Inc | $138.71 | -1.1% | $39.2B | 27.9 | 5.5 | 21.33% | 0.74% |
 BIO | Bio-Rad Laboratories Inc | $326.72 | -0.2% | $8.8B | 53.8 | 1.3 | 2.5% | - |
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
| MDT | Medtronic Plc | $85.71 | -2.1% | $109.7B | 23.0 | 2.2 | 9.85% | 3.38% |
| SYK | Stryker Corp | $348.04 | -1.2% | $133.4B | 40.3 | 5.8 | 15.2% | 1.01% |
✅ Danaher investor checkpoints
Key checkpoints to monitor when investing in Danaher. Bioprocessing cycle recovery, diagnostics and tools demand trends, progress on acquisition integration, and capital return policy all act as key short- and medium-term variables.
| Checkpoint | What to Check | Current Status |
|---|---|---|
| Bioprocessing | Bioprocessing revenue and inventory adjustment trends | Recovery phase |
| Diagnostics & Tools | Clinical diagnostics and life sciences revenue flow | Holding steady |
| Acquisition & Redeployment | Progress on new asset integration | Expansion in progress |
| Capital Return | Share buyback and dividend trends | Steady return flow |
As a representative core holding in the global healthcare tools and diagnostics industry, Danaher's diversified business segment portfolio and operating-model-driven value creation are appealing, with the bioprocessing cycle and macro swings as the key variables to monitor. Investors seeking long-term healthcare exposure are advised to consider phased buying and a long-term perspective.
이 글은 2026년 5월 21일 기준 정보입니다.